Sabby Management’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

Sabby Management’s Portfolio EYEGW Stock Details EYEGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,604	Closed	-$6K	–	348
2016 Q4	$6K	Sell	20,604 -26,364	-56%	-$10.4K	﹤0.01%	293
2016 Q3	$16K	Sell	46,968 -6,925	-13%	-$3.55K	﹤0.01%	306
2016 Q2	$2K	Sell	53,893 -11,500	-18%	-$8.15K	﹤0.01%	287
2016 Q1	$49K	Sell	65,393 -108,757	-62%	-$75.3K	﹤0.01%	281
2015 Q4	$131K	Sell	174,150 -25,850	-13%	-$21.7K	0.01%	294
2015 Q3	$204K	Buy	+200,000	New	+$247K	0.01%	348

Other funds holding EYEGW

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sabby Management's EYEGW Position: Q1 2017 in Review

Sabby Management sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q1 2017, closing a stake of 20,604 shares — an estimated $6K sold.

Sabby Management first reported a position in EYEGW in Q3 2015 and held it in 6 quarters. The position peaked at $204K in Q3 2015. 5 funds tracked by Wall St. Rank hold EYEGW as of Q1 2017.

Sabby Management reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 20,604 Eyegate Pharmaceuticals, Inc. Warrants shares in Q1 2017, an estimated $6K.
Sabby Management first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q3 2015 and held it in 6 quarters.
Sabby Management's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $204K in Q3 2015.
5 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.